U.S. markets closed

SenesTech, Inc. (SNES)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5600+0.0100 (+0.65%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close1.5500
Open1.5400
Bid1.5400 x 1300
Ask1.5800 x 1200
Day's Range1.5400 - 1.5800
52 Week Range1.3000 - 3.2000
Volume53,120
Avg. Volume232,731
Market Cap19.018M
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-1.0770
Earnings DateNov 09, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SenesTech, Inc.
    Analyst Report: ICON Public Limited CompanyIcon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
    Rating
    Fair Value
    Economic Moat
    27 days agoMorningstar
View more
  • Simply Wall St.

    We Think SenesTech (NASDAQ:SNES) Needs To Drive Business Growth Carefully

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • PR Newswire

    SenesTech Announces 2021 Second Quarter Financial and Operational Results

    SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the first and only EPA registered rat contraceptive, ContraPest®, announced today revenues for the second quarter of 2021 increased 125% from the same period a year ago, and are up 82% sequentially. Year to date, revenues have increased 130% from the same period last year. The growth is driven by continued adoption of ContraPest across its key market segments an

  • PR Newswire

    SenesTech to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021

    SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, will report financial results for its second quarter 2021, ended June 30, 2021, after the market close on Thursday, August 12, 2021. The Company has scheduled a conference call that same day, Thursday, August 12, 2021, at 5:00 pm ET, to review the results.